These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2678426)

  • 1. Prazosin treatment of neurological patients with detrusor hyperreflexia and bladder emptying disability.
    Petersen T; Husted SE; Sidenius P
    Scand J Urol Nephrol; 1989; 23(3):189-94. PubMed ID: 2678426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia--a double-blind, placebo-controlled clinical trial.
    Stöhrer M; Madersbacher H; Richter R; Wehnert J; Dreikorn K
    Spinal Cord; 1999 Mar; 37(3):196-200. PubMed ID: 10213329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder.
    Kakizaki H; Ameda K; Kobayashi S; Tanaka H; Shibata T; Koyanagi T
    Int J Urol; 2003 Nov; 10(11):576-81. PubMed ID: 14633081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction.
    Utomo E; Groen J; Blok BF
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004927. PubMed ID: 24859260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
    Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
    J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uninhibited neurogenic bladder treated with Prazosin.
    Jensen D
    Scand J Urol Nephrol; 1981; 15(3):229-33. PubMed ID: 7323743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Personal experiences with phenoxybenzamine (Dibenzyran) in the treatment of functional disorders of bladder emptying].
    Wehnert J; Sage S
    Z Urol Nephrol; 1988 Mar; 81(3):153-8. PubMed ID: 3388995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity.
    Kuo HC
    Urology; 2003 Mar; 61(3):550-4. PubMed ID: 12639645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study.
    Lazzeri M; Calò G; Spinelli M; Guerrini R; Salvadori S; Beneforti P; Sandri S; Regoli D; Turini D
    Urology; 2003 May; 61(5):946-50. PubMed ID: 12736013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of flavoxate on hyperactive detrusor muscle.
    Jonas U; Petri E; Kissel J
    Eur Urol; 1979; 5(2):106-9. PubMed ID: 421699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurogenic failures of the external urethral sphincter closure and relaxation; a videourodynamic study.
    Sakakibara R; Hattori T; Uchiyama T; Yamanishi T; Ito H; Ito K
    Auton Neurosci; 2001 Jan; 86(3):208-15. PubMed ID: 11270099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, double-blind, placebo-controlled trial of the efficacy of prazosin in the treatment of dysuria associated with benign prostatic hypertrophy.
    Le Duc A; Cariou G; Baron C; Cukier J; Quentel P; Faure G; Rambeaud JJ; Navratil H; Costa P; Richaud JJ
    Urol Int; 1990; 45 Suppl 1():56-62. PubMed ID: 1690483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder neck anesthesia and resection in women with detrusor hyperreflexia.
    Petersen T; Erichsen C
    Urol Int; 1987; 42(3):190-4. PubMed ID: 3617256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients.
    Gallien P; Reymann JM; Amarenco G; Nicolas B; de Sèze M; Bellissant E
    J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1670-6. PubMed ID: 16291892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride.
    Bary PR; Moisey CU; Stephenson TP; Brendler CB
    Prog Clin Biol Res; 1981; 78():313-9. PubMed ID: 7038709
    [No Abstract]   [Full Text] [Related]  

  • 16. Urodynamic effects of intravesical instillation of atropine and phentolamine in patients with detrusor hyperactivity.
    Ekström B; Andersson KE; Mattiasson A
    J Urol; 1993 Jan; 149(1):155-8. PubMed ID: 8417203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of urodynamic studies to assess the effect of pharmacological agents with particular references to alpha-adrenergic blockade.
    Thomas DG; Philp NH; McDermott TE; Rickwood AM
    Paraplegia; 1984 Jun; 22(3):162-7. PubMed ID: 6205351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alpha adrenergic blocking agents in disorders of the bladder sphincter].
    Perrigot M; Vannier A; Bor Y
    Rev Prat; 1986 Jan; 36(5):223-8. PubMed ID: 2421393
    [No Abstract]   [Full Text] [Related]  

  • 19. A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia.
    Chapple CR; Stott M; Abrams PH; Christmas TJ; Milroy EJ
    Br J Urol; 1992 Sep; 70(3):285-94. PubMed ID: 1384919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of bladder dysfunction to lesion site in multiple sclerosis.
    Araki I; Matsui M; Ozawa K; Takeda M; Kuno S
    J Urol; 2003 Apr; 169(4):1384-7. PubMed ID: 12629367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.